ACE inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) vs placebo, CKD
Polypharmacy guidance: realistic prescribing
Study population:
Patients with heart failure and Chronic Kidney Disease
(NYHA class I - IV) due to left ventricular systolic dysfunction (ejection fraction ≤0.35).
eGFR <60 mL /min /1.73m2
Comments:
Mean age of patients was 64 years. Approximately 75% were male.
| Outcome | Duration | NNT | Annualised NNT |
|---|---|---|---|
| Prevent one death (any cause) | 34 months (mean followup) |
29 |
101 |